A chimeric human-cat Fcγ-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen
- 31 July 2006
- journal article
- Published by Elsevier BV in Clinical Immunology
- Vol. 120 (1), 45-56
- https://doi.org/10.1016/j.clim.2005.12.010
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?Journal of Applied Physiology, 2004
- Rapid venom immunotherapy updateCurrent Opinion in Allergy and Clinical Immunology, 2003
- Systemic Reactions to Allergen Immunotherapy: A Review of the LiteratureImmunopharmacology and Immunotoxicology, 2003
- Activating and inhibitory signaling in mast cells: New opportunities for therapeutic intervention?Journal of Allergy and Clinical Immunology, 2000
- FcRECEPTOR BIOLOGYAnnual Review of Immunology, 1997
- Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivityAllergy, 1997
- Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FeγRIIBNature, 1996
- The same tyrosine-based inhibition motif, in the intra-cytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activationImmunity, 1995
- Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes.JCI Insight, 1990
- VACCINATION AGAINST HAY FEVER: REPORT OF RESULTS DURING THE LAST THREE YEARS.The Lancet, 1914